WORLD MEDICAL INNOVATION FORUMSM CANCER | APRIL 25–27, 2016 World Medical Innovation Forum

PARTNERS HEALTHCARE

Headquartered in Boston, The World Medical Innovation Forum is a global Massachusetts, Partners HealthCare gathering of more than 1,200 senior health care is one of the nation's most highly leaders hosted by Partners HealthCare in the regarded hospital systems. Its founding institutions, Brigham and heart of Boston. It was established to respond to Women’s Hospital and Massachusetts the intensifying transformation of health care and General Hospital, are staffed by its impact on innovation. The Forum is rooted in Harvard Medical School faculty the belief that no matter the magnitude of that and have a legacy of innovation change, the center of health care needs to be a that includes 18 Nobel Laureates and therapies that have redefined shared, fundamental commitment to collaborative the contemporary standard of care. innovation – industry and academia working It's the largest academic research together to improve patient lives. enterprise in the nation at more than $1.5 billion of annual research. The 2016 World Medical Innovation Forum will Its staff is responsible for hundreds feature the newest technologies to diagnose, treat of products and best practices and manage cancer. that benefit millions of patients worldwide.

CANCER | April 25–27, 2016 CARDIOVASCULAR | May 1–3, 2017 Keynoters

Joseph Jimenez Giovanni Caforio, MD CEO, Novartis CEO, Bristol-Myers Squibb Robert Bradway Richard Gonzalez CEO, Amgen CEO, AbbVie Robert Mulroy Michael Pellini, MD CEO, Merrimack Pharmaceuticals CEO, Foundation Medicine Briggs Morrison, MD David Schenkein, MD CEO, Syndax Pharmaceuticals CEO, Agios Pharmaceuticals David Lee Bruno Strigini CEO, Lumicell President, Novartis Oncology Marc de Garidel William Hait, MD, PhD Chairman and CEO, Ipsen Global Head, Janssen R&D, J&J Paul Hudson Gary Reedy President, AstraZeneca US, CEO, American Cancer Society Executive Vice President, Thomas Lynch, MD AstraZeneca North America CEO, Mass General David Torchiana, MD Physician’s Organization CEO, Partners HealthCare Monica Bertagnolli, MD Daniel Haber MD, PhD Chief, Division of Surgical Oncology, Director, Massachusetts General Hospital Brigham and Women’s Hospital, Cancer Center, Kurt J. Isselbacher/Peter D. Professor of Surgery, Schwartz Professor of Oncology, Harvard Medical School Harvard Medical School Judy Salerno, MD Glenn Dranoff, MD CEO, Susan G. Komen for the Cure Global Head of Exploratory Immuno- William Sellers, MD Oncology, Novartis Institutes for Vice President and Global Head of Biomedical Research Oncology, Novartis Institutes for Christopher Viehbacher BioMedical Research Managing Partner, Gurnet Point Capital Nancy Snyderman, MD Henri Termeer Medical Advisor, Jean-François Formela, MD GE Healthymagination Partner, Atlas Venture Amir Nashat, PhD Bob Tepper, MD Managing Partner, Polaris Partners Partner, Third Rock Ventures Jim Robinson Kathy Giusti President, Americas Operations, Astellas Founder and Executive Chairman, MMRF Francis Cuss, MD Executive Vice President and Chief Scientific Officer, R&D, Bristol-Myers Squibb

Every Speaker an Expert. Every Panel Unique. Every Seat Invaluable. Featured speakers include more than 100 CEOs, top cancer innovators, leading investors, and national journalists. Sponsors Panels

PRESENTING MON. APRIL 25, 2016 8:00 AM - 8:00 PM TUES. APRIL 26, 2016 8:15 AM - 6:30 PM WED. APRIL 27, 2016 STAKEHOLDER 8:10 AM - 12:35 PM

A War or Moonshot: Where Do We Stand? Arms Race in Radiation Breakthrough Devices to Treat Cancer Cancer Diagnostics: New Uses, New Reimbursements? Combination Cancer Therapies: Drug Resistance and Therapeutic Index STRATEGIC Creating a Disruptive Cancer Pipeline Curative Therapies: The Economics of Game Changing Science Discovery Café: Enjoy Lunch with Top Cancer Leadership from across Partners HealthCare Disruptive Dozen Early Detection and Prevention of Cancer Epigenetics and Novel Cancer Targets Financing Breakthrough Cancer Companies COLLABORATORS First Look: The Next Wave of Cancer Breakthroughs Global Cancer Markets Immunotherapy I: Checkpoint Activation and Cancer Vaccines Immunotherapy II: Cell Based Therapies New Philanthropy: Patients Driving Innovation Study Designs to Meet the Challenges of Personalized Cancer Medicine Surviving Cancer: New Realities, New Needs Winning Portfolio Strategy EXCLUSIVE MEDIA PARTNER Breakthrough Technologies

FIRST LOOK The Next Wave of Cancer Breakthroughs Monday Morning | 8AM – 12PM DISCOVERY CAFÉ LUNCH Enjoy Lunch with Top Cancer Leadership Please join us as some of our most creative investigators from across Partners HealthCare describe their most promising commercially related research. Rapid-fire presentations by two dozen early-career Monday Lunch | 12PM – 1:30PM Harvard Medical School faculty will highlight compelling Top faculty from Brigham and Women's Hospital, new discoveries and insights that will be the cancer care Massachusetts General Hospital and Dana-Farber Cancer products of the future. If identifying new high impact cancer Institute will host intimate lunch discussions on developments technology is your passion—as an investor, company leader, in their field and their own research. Forum attendees are donor, entrepreneur or investigator—this session is for you. invited to engage with these internationally renowned leaders These young stars from Brigham and Women's Hospital, on topics ranging from the integration of specific oncology Massachusetts General Hospital and Dana-Farber Cancer therapies to the newest diagnostic methods. This will be an Institute will each describe their work in highly organized exciting and energized session with abundant opportunities 10-minute sessions. for direct exchanges with these world leaders. Open registration for tables by topic/speaker (8 guests per table) is Speakers available as part of World Forum registration. All speakers are affiliated with Harvard Medical School Cyril Benes, PhD, MGH Speakers Priscilla Brastianos, MD, MGH All speakers are affiliated with Harvard Medical School Mark Cobbold, MD, PhD, MGH Kenneth Anderson, MD, BWH Jeannie Lee, MD, PhD, MGH Ryan Corcoran, MD, PhD, MGH Monica Bertagnolli, MD, BWH Maximo Loda, MD, BWH Shawn Demehri, MD, PhD, MGH Joan Brugge, PhD, HMS Jay Loeffler, MD, MGH Daniela Dinulescu, PhD, BWH George Demetri, MD, Robert Martuza, MD, MGH Wilhelm Haas, PhD, MGH Dana-Farber Marcela Maus, MD, PhD, Lida Hariri, MD, PhD, MGH Don Dizon, MD, MGH MGH Aditi Hazra, PhD, BWH David Fisher, MD, PhD, MGH Ann Partridge, MD, Jayender Jagadeesan, PhD, BWH Keith Flaherty, MD, MGH Dana-Farber Hakho Lee, PhD, MGH Levi Garraway, MD, PhD, Scott Rodig, MD, PhD, BWH Alexander Lin, PhD, BWH Dana-Farber Deborah Schrag, MD, BWH, Dana-Farber Sandra McAllister, PhD, BWH Jeffrey Golden MD, BWH Arlene Sharpe, MD, PhD, Mikael Pittet, PhD, MGH Daniel Haber, MD, PhD, MGH BWH, Dana-Farber Miguel Rivera, MD, MGH Elizabeth Henske, MD, BWH, Dana-Farber Julie Silver, MD, Spaulding Sandro Santagata, MD, PhD, BWH Theodore Hong, MD, MGH Kimberly Stegmaier, MD, Shiladitya Sengupta, PhD, BWH Dana-Farber John Iafrate, MD, MGH Paul Shyn, MD, BWH Guillermo Tearney, MD, PhD, Katherine Janeway, MD, Matthew Steinhauser, MD, BWH MGH Dana-Farber Shannon Stott, PhD, MGH Ralph Weissleder, MD, PhD, Keith Joung, MD, PhD, MGH Mario Suva, MD, PhD, MGH MGH Cigall Kadoch, PhD, Jonathan Whetstine, PhD, David Ting, MD, MGH Dana-Farber MGH Featured Speakers

Kenneth Anderson, MD George Demetri, MD Kathy Giusti Director, Jerome Lipper Multiple Myeloma Director, Center for Sarcoma and Bone Founder and Executive Chairman, MMRF Center, Kraft Family Professor of Medicine, Oncology, Senior Vice President for Jeffrey Golden, MD Harvard Medical School Experimental Therapeutics, Institute Chair of Pathology, Brigham and Women's Usman Azam, MD Physician, Dana-Farber Cancer Institute Hospital, Ramzi S. Cotran Professor of Global Head, Cell & Gene Therapies Sheila Dharmarajan Pathology, Harvard Medical School Unit, Novartis Head of Business Development, Richard Gonzalez Julia Beaver, MD Zelnick Media Capital CEO, AbbVie Acting Clinical Team Leader, Division Keith Dionne, PhD Marc Grodman, MD of Oncology Products 1, CDER, FDA CEO, Constellation Pharmaceuticals CEO, BioReference Laboratories Monica Bertagnolli, MD Don Dizon, MD Daphne Haas-Kogan, MD Chief, Division of Surgical Oncology, Clinical Co-Director, Gynecologic Chair, Department of Radiation Oncology, Brigham and Women's Hospital, Oncology, Massachusetts General Dana-Farber Cancer Institute, Professor of Surgery, Hospital, Associate Professor of Professor of Radiation Oncology, Harvard Medical School Medicine, Harvard Medical School Harvard Medical School James Bradner, MD Glenn Dranoff, MD Daniel Haber, MD, PhD President, Novartis Institutes Global Head of Exploratory Immuno- Director, Massachusetts General for BioMedical Research Oncology, Novartis Institutes for Hospital Cancer Center, Kurt J. Robert Bradway Biomedical Research Isselbacher/Peter D. Schwartz Professor of CEO, Amgen Jens Eckstein, PhD Oncology, Harvard Medical School Troy Brennan, MD President, SR One Nir Hacohen, PhD EVP and CMO, CVS Health Helmy Eltoukhy, PhD Immunologist, MGH Center for Joan Brugge, PhD CEO, Guardant Health Immunology and Inflammatory Diseases, Professor, Director, Ludwig Center, Jeffrey Engelman, MD, PhD MGH Research Scholar, Harvard Medical School Director, Thoracic Oncology and Director, Associate Professor, Medicine, Harvard Medical School Giovanni Caforio, MD Molecular Therapeutics, Medical CEO, Bristol-Myers Squibb Oncology, Massachusetts General Hospital, William Hait, MD, PhD Laurel Schwartz Associate Professor of Global Head, Janssen R&D, J&J Bruce Chabner, MD Medicine, Harvard Medical School Cancer Center Clinical Director Sean Harper, MD Emeritus, Massachusetts General Maurice Ferre, MD Executive Vice President, Hospital, Professor, Department of CEO, Insightec Research and Development, Amgen Medicine, Harvard Medical School Tim Ferris, MD Theodore Hong, MD Andy Chan, MD Senior Vice President of Population Health Director, Gastrointestinal Radiation Program Director, Gastroenterology Management, Partners HealthCare Oncology, Massachusetts General Training Program, Massachusetts General David Fisher, MD, PhD Hospital, Associate Professor of Radiation Hospital, Associate Professor of Medicine, Chief, Dermatology, Oncology, Harvard Medical School Harvard Medical School Massachusetts General Hospital, Edward Paul Hudson Antonio Chiocca, MD, PhD Wigglesworth Professor of Dermatology, President, AstraZeneca US, Chairman, Neurosurgery, Brigham and Harvard Medical School Executive Vice President, Women's Hospital Professor of Surgery, Keith Flaherty, MD AstraZeneca North America Harvard Medical School Director, Clinical Research, Cancer John Iafrate, MD, PhD Robert Copeland, PhD Center, Massachusetts General Associate in Pathology, Medical Director, President of Research and Hospital, Associate Professor of Center for Integrated Diagnostics, Chief Scientific Officer, Epizyme Medicine, Harvard Medical School Massachusetts General Hospital, Professor of Pathology, Harvard Medical School Newt Crenshaw Pat Fortune, PhD Vice President of North America Senior Market Sector Leader, Joseph Jachinowski Oncology, Eli Lilly Partners Innovation CEO, Mevion Medical Systems Francis Cuss, MD Jean-François Formela, MD Katherine Janeway, MD Executive Vice President Partner, Atlas Ventures Associate Physician, Dana-Farber and Chief Scientific Officer, R&D, Jamie Freedman, MD, PhD Cancer Institute, Assistant Professor, Bristol-Myers Squibb Senior Vice President, Global Clinical Harvard Medical School Thomas Daniel, MD Development MedImmune Joseph Jimenez Chairman, Celgene Research Mark Frohlich, MD CEO, Novartis Marc de Garidel EVP, Portfolio Strategy, Juno Therapeutics Keith Joung, MD, PhD CEO, Ipsen Levi Garraway, MD, PhD The Jim and Ann Orr MGH Research Scholar, Associate Chief of Pathology for Louis DeGennaro, PhD Director, Center for Cancer Precision Medicine, Assistant Professor of Medicine, Research, Pathologist, Massachusetts CEO, The Leukemia General Hospital, Professor of Pathology, & Lymphoma Society Medical Oncology Service, Dana-Farber Cancer Institute, Associate Professor of Harvard Medical School Medicine, Harvard Medical School Cigall Kadoch, PhD Briggs Morrison, MD Nancy Simonian, MD Principal Investigator, Pediatric Oncology, CEO, Syndax Pharmaceuticals CEO, Syros Pharmaceuticals Dana-Farber Cancer Institute, Robert Mulroy Peter Slavin, MD Assistant Professor, Pediatrics, CEO, Merrimack Pharmaceuticals President, Massachusetts General Harvard Medical School Betsy Nabel, MD Hospital, Professor of Healthcare Policy, Rajiv Kaul President, Brigham and Women's Harvard Medical School Portfolio Manager and Research Analyst, Hospital, Professor of Medicine, Andy Slavitt Fidelity Investments Harvard Medical School Acting Administrator, CMS Anne Klibanski, MD Amir Nashat, PhD Nancy Snyderman, MD Chief Academic Officer, Managing Partner, Polaris Partners Medical Advisor, Partners HealthCare, Laurie Carrol GE Healthymagination Guthart Professor of Medicine, Ann Partridge, MD Harvard Medical School Director, Adult Survivorship Program, Risa Stack, PhD Program for Young Women with Breast General Manager, New Business Creation, Maria Koehler, MD, PhD Cancer, Dana-Farber Cancer Institute, GE Ventures Vice President, Strategy, Associate Professor of Medicine, Billy Starr Innovation and Collaborations, Harvard Medical School Pfizer Oncology Business Unit Founder & Executive Director, Michael Pellini, MD Pan-Mass Challenge Krishna Kumar CEO, Foundation Medicine CEO, Emerging Business, Phillips Kimberly Stegmaier, MD Amy Pollack, MD Associate Professor, Dana-Farber Cancer Peter Lebowitz, MD, PhD Vice President, Medical Affairs, CMO, Institute, Harvard Medical School Global Therapeutic Area Head, Surgical Businesses and Developed Oncology, Janssen R&D Bruno Strigini Markets, Covidien President, Novartis Oncology David Lee Gary Reedy CEO, Lumicell Guillermo Tearney, MD, PhD CEO, American Cancer Society Pathology, Mike and Sue Hazard Family Jeannie Lee, MD, PhD David Reese, MD MGH Research Scholar, Massachusetts Professor of Genetics, Senior Vice President, General Hospital, Professor of Pathology, Massachusetts General Hospital Translational Sciences, Amgen Harvard Medical School Jonathan Leff Alessandro Riva, MD Robert Tepper, MD Partner, Deerfield Management Global Head, Oncology Development and Partner, Third Rock Ventures, Adjunct Gillian Leng, MD Medical Affairs, Novartis Oncology Professor, Harvard Medical School Deputy Chief Executive and Director James Robinson Henri Termeer of Health and Social Care, NICE President, Astellas Pharma US Claire Thom, PharmD Nick Leschly Scott Rodig, MD, PhD Senior Vice President, Global Oncology CEO, Bluebird Bio Associate Professor, Development, Astellas Neal Lindeman, MD Brigham and Women's Hospital Meg Tirrell Associate Pathologist, Pathology, Phil Rowlands, PhD Biotech and Pharma Reporter, CNBC Brigham and Women's Hospital, Interim Head, Oncology, David Torchiana, MD Associate Professor, Pathology, Therapeutic Area Unit, Takeda Harvard Medical School CEO, Partners HealthCare Judy Salerno, MD Mike Vasconcelles, MD Massimo Loda, MD CEO, Susan G. Komen for the Cure Senior Pathologist, Principal Investigator, CMO, Unum Therapeutics Brigham and Women's Hospital, David Schenkein, MD Christopher Viehbacher Dana-Farber Cancer Institute, Professor, CEO, Agios Pharmaceuticals Managing Partner, Department of Pathology, Deborah Schrag, MD Gurnet Point Capital Harvard Medical School Chief, Division of Population Sciences, Ralph Weissleder, MD, PhD Jay Loeffler, MD Medical Oncology, Dana-Farber Cancer Director, Center for Systems Biology, Chair, Radiation Oncology, Massachusetts Institute Professor, Medicine, Massachusetts General Hospital, General Hospital, Herman and Joan Suit Harvard Medical School Professor, Radiology and Systems Professor of Radiation Oncology, William Sellers, MD Biology, Harvard Medical School Harvard Medical School Vice President and Global Head of Johnathan Whetstine, PhD David Louis, MD Oncology, Novartis Institutes for Tepper Family MGH Research Scholar, Pathologist-in-Chief, Massachusetts BioMedical Research Associate Professor of Medicine, General Hospital, Benjamin Castleman Arlene Sharpe, MD, PhD Harvard Medical School Professor of Pathology, Leader, Cancer Immunology Brigham and Chuck Wilson, PhD Harvard Medical School Women's Hospital, Dana-Farber Cancer CEO, Unum Therapeutics Thomas Lynch, MD Institute, George Fabyan Professor of Comparative Pathology, Dow Wilson CEO, Mass General CEO, Varian Medical Systems Physician's Organization Harvard Medical School Sue Siegel Mallika Marshall, MD Note: Speakers subject to change. Health Reporter, WBZ-TV/CBS Boston CEO, GE Ventures and Healthymagination Marcela Maus, MD, PhD Julie Silver, MD Director of Cellular Immunotherapy, Staff Physiatrist, Spaulding Rehabilitation Massachusetts General Hospital, Assistant Hospital, Associate Professor, Associate Professor, Harvard Medical School Chair for Strategic Initiatives, Department of Physical Medicine and Rehabilitation, Harvard Medical School Join Us for the 2016 World Medical Innovation Forum

Experience the state-of-the-art in cancer technology, care, and research

Understand the prospects for innovation in a transformed health care industry

See firsthand the breakthrough cancer technologies from across the industry

Forge relationships and exchange information with world-recognized clinicians, investors, entrepreneurs, scientists, CEOs, executives, government leaders, philanthropists, and journalists

BROUGHT TO YOU BY:

215 First Street, Suite 500 | Cambridge, MA 02142 worldmedicalinnovation.org